Ocular Therapeutix, Inc. announced the appointment of Jonathan H. Talamo, M.D. to the position of Chief Medical Officer. In this role, Dr. Talamo will help advance Ocular's development pipeline, including lead therapeutic candidate, DEXTENZATM. Dr. Talamo currently serves as an Associate Professor of Ophthalmology at Harvard Medical School and as Director of the Massachusetts Eye and Ear Infirmary (MEEI) Waltham.

Dr. Talamo is also Chairman of the Program Committee and on the Executive Board of the New England Ophthalmological Society.